Insider buying last 90 days
No open-market insider purchases were filed for TECH in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every TECH insider filing, plotted on the chart in Gekko.Open TECH in Gekko
NASDAQ: TECH
Bio-Techne (TECH) Stock Analysis & Forecast
Sep 28 close
$72.51−0.10 (−0.1%)
Gekko Brief
AI summaryBio-Techne shares touched a new 52-week high this week, trading as high as $72.70, as shareholders approved the company's acquisition by Merck KGaA for $73.00 per share, valuing the deal at approximately $11.3 billion. The Hart-Scott-Rodino antitrust waiting period in the U.S. has expired, though the transaction still awaits further regulatory approvals and is expected to close in late 2026 or early 2027. Shareholders also rejected the company's pay package alongside their approval of the merger terms.
The stock closed at $72.51, essentially flat on the day, sitting above both its 50-day average of $72.21 and its 200-day average of $61.78, with the shorter average above the longer one. The GekkoIndex reads 49.9, placing it in the Neutral zone. Price stands 22.9% above Gekko Fair Value of $59.02, a gap that reflects the pending deal terms near $73.00 per share.
Bio-Techne's next earnings report is scheduled for 4 November 2026, before the open, 36 days away and outside a typical 20-trading-day holding window. No insider, Congress or unusual options activity appears in the recent 30-day and 90-day windows. Seasonality from this point in the calendar has averaged a 1% gain over the next 20 trading days across 5 years, rising in 3 of them. Five covering analysts currently hold a consensus hold rating, with a consensus target of $70.73, below the current price.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Bio-Techne price vs fair value
Close $72.51200-day averageGekko Fair Value $59.02
Bio-Techne quick facts
- Market cap
- $11.35B
- P/E ratio
- 62.6
- Forward P/E
- 34.6
- EPS, TTM
- $1.16
- Revenue, TTM
- $1.22B
- Profit margin
- 15%
- Dividend yield
- 0.44%
- Beta
- 1.27
- Volume
- 3.63M avg 2.92M
- 1-year return
- +43.6%
- Typical daily move
- ±0.2%
- Typical 20-day move
- ±6.7%
- 50-day average
- $72.21
- 200-day average
- $61.78
- Next earnings
- Nov 4 before open
- Shares outstanding
- 156.8M
Bio-Techne swing-trade checklist
Bio-Techne scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $72.51 is above the 50-day ($72.21) and 200-day ($61.78) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
49.9, Neutral
Reading 49.9 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
22.9% above
Price is 22.9% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+1.0% on average
From this point in the calendar, the next 20 trading days averaged +1% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Bio-Techne stock chart and price history
Bio-Techne closed at $72.51 on Sep 28, 2026, +43.6% over the past year, inside a 52-week range of $43.20 to $72.69.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +0.1%
- 3 months
- +2.3%
- 6 months
- +42.3%
- 1 year
- +43.6%
The full TECH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TECH in Gekko
Follow Bio-Techne through every session
Put TECH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track TECH in GekkoFree for 7 days. No credit card required.
About Bio-Techne
Bio-Techne makes and sells reagents, instruments, and services used across life science research, diagnostics, and bioprocessing work. It is recognized for its biological reagents such as cytokines, growth factors, antibodies, and cell selection tools, along with proteomic instruments built for automated western blot and multiplexed ELISA testing.
The company is structured into two segments. Its Protein Sciences segment supplies reagents and analytical instruments applied to research, diagnostics, and cell and gene therapy work, including protein quantification tools for biological fluids. Its Diagnostics and Genomics segment produces diagnostic controls, calibrators, and assays for regulated diagnostic markets, along with exosome-based molecular diagnostics, spatial genomic and tissue biopsy assays, and products used in genetic carrier screening, oncology diagnostics, hematology, blood chemistry, gases, and coagulation testing.
Bio-Techne was formerly named Techne Corporation before taking its current name in November 2014, and it was incorporated in 1976. It is headquartered in Minneapolis, Minnesota, and its shares are listed on the NASDAQ under the ticker TECH.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- bio-techne.com
Bio-Techne GekkoIndex: the smart money zone
Bio-Techne’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 49.9, in the Neutral zone, up 0.7 points over five sessions.
49.9Neutral
Up 0.7 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 38 | +0.9% | +3.3% | ||
| Accumulation | 245 | +1.1% | +3.2% | ||
| Neutral (current zone) | 346 | −0.5% | −0.8% | ||
| Distribution | 37 | −0.2% | −3.6% | ||
| Selling | 6 | Too few readings yet | |||
Average TECH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the TECH price, zone by zone.Track TECH in Gekko
Is Bio-Techne stock overvalued? Gekko Fair Value
Bio-Techne trades 22.9% above Gekko Fair Value of $59.02, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Bio-Techne shares are worth, recalculated every trading day.
$59.02
Gekko Fair Value, Sep 26, 2026
22.9% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open TECH in Gekko
Bio-Techne insider and Congress trading
No open-market insider purchases were filed for Bio-Techne, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in TECH were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for TECH, plotted on the chart in Gekko.Open TECH in Gekko
Buybacks
Bio-Techne has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $41.65M
- As a share of market cap
- 0.37%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
2of the funds Gekko tracks hold TECH.
0added1opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Bio-Techne earnings: next date and track record
Bio-Techne reports on Nov 4, 2026, before the open (36 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 36 days away
- EPS estimate
- $0.46
- Revenue estimate
- $292.4M
5 of 8reports beat the EPS estimate
±5.4%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| May 6, 2026 | $0.00 est $0.54 | $311.4M est $316.1M | −10.2% |
| Feb 4, 2026 | $0.46 est $0.43 | $295.9M est $290.5M | +1.9% |
| Nov 5, 2025 | $0.42 est $0.42 | $286.6M est $291.3M | −4.8% |
| Aug 6, 2025 | $0.53 est $0.50 | $317.0M est $294.6M | −8.2% |
| May 7, 2025 | $0.56 est $0.51 | $316.2M est $325.5M | +4.3% |
| Feb 5, 2025 | $0.42 est $0.39 | $297.0M est $317.5M | +3.4% |
| Oct 30, 2024 | $0.42 est $0.38 | $289.5M est $280.3M | +4.3% |
| Aug 7, 2024 | $0.49 est $0.49 | $306.1M est $306.5M | −6.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Bio-Techne stock forecast and analyst price targets
Analysts’ average 12-month price target for Bio-Techne is $70.73, −2.5% from the last close, from 5 firms rating the stock in the last 90 days.
$70.73consensus 12-month target, −2.5% from the last close
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 14 | Wells Fargo | $73 | +0.7% |
| Aug 12 | RBC Capital | $73 | +0.7% |
| Aug 12 | William Blair | — | — |
| Jul 8 | RBC Capital | $73 | +0.7% |
| Jun 30 | Benchmark Co. | — | — |
−0.8%average 20-day move after past Neutral readings
+1.0%average move over the next 20 trading days in the last 5 years
±0.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Bio-Techne seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Bio-Techne averaged +1.0% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.1% | 3 of 5 |
| Next 10 trading days | +1.3% | 2 of 5 |
| Next 15 trading days | +1.3% | 2 of 5 |
| Next 20 trading days | +1.0% | 3 of 5 |
| Next 30 trading days | +2.3% | 3 of 5 |
For scale, TECH’s typical 20-trading-day move in either direction is about 6.7%.
Bio-Techne market cap and key statistics
Bio-Techne’s market cap is $11.35B, with a P/E ratio of 62.6 and revenue of $1.22B over the last twelve months.
Valuation
- Market cap
- $11.35B
- P/E ratio
- 62.6
- Forward P/E
- 34.6
- EPS, TTM
- $1.16
- Gekko Fair Value
- $59.02
Trading
- Volume
- 3.63M
- Avg volume, 20 days
- 2.92M
- 52-week high
- $72.69
- 52-week low
- $43.20
- Shares outstanding
- 156.8M
Financials
- Revenue, TTM
- $1.22B
- Profit margin
- 15%
- Return on equity
- 9%
- Quarterly earnings growth, YoY
- +128.6%
Risk and income
- Beta
- 1.27
- Typical daily move
- ±0.2%
- Typical 20-day move
- ±6.7%
- Dividend yield
- 0.44%
Bio-Techne stock news this week
Coverage of Bio-Techne this week reads positive: 7 positive, 5 neutral and 0 negative headlines.
- Bio-Techne (NASDAQ:TECH) Reaches New 52-Week High – Time to Buy?Defense World, Sep 28
- Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay PackageYahoo Finance, Sep 26
- Form 4 Bio-Techne Corp For: 25 September By Investing.comInvesting.com South Africa, Sep 25
- Bio-Techne (TECH) director exercises options and delivers or withholds 5,559 shares for costs or taxes.Stock Titan, Sep 24
- Form 8K Bio-Techne Corp For: 23 September By Investing.comInvesting.com Canada, Sep 23
- Form 8K Bio-Techne Corp For: 23 SeptemberInvesting.com India, Sep 23
Bio-Techne peers
Bio-Techne’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
Bio-Techne stock FAQ
What is Bio-Techne’s market cap?
Bio-Techne’s market cap is $11.35B at the Sep 28, 2026 close of $72.51, with 156.8M shares outstanding. The shares trade on a P/E ratio of 62.6.
What is the Bio-Techne stock forecast?
The consensus analyst 12-month price target for Bio-Techne is $70.73, −2.5% from the last close. Of the 5 firms that rated the stock in the last 90 days, 0 rate it a buy, 5 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Bio-Techne stock overvalued or undervalued?
On Gekko’s estimate Bio-Techne is overvalued: the Sep 28, 2026 close of $72.51 is 22.9% above Gekko Fair Value of $59.02. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Bio-Techne report earnings next?
Bio-Techne is expected to report on Nov 4, 2026, before the market opens (36 days away). Analysts expect earnings of $0.46 per share on revenue of $292.4M. Bio-Techne beat the earnings estimate in 5 of its last 8 reports, moving 5.4% on average across the report.
What is Bio-Techne’s 52-week high and low?
Bio-Techne’s 52-week high is $72.69 and its 52-week low is $43.20; it closed at $72.51 on Sep 28, 2026, +43.6% over the past year. Over the last five years the shares peaked at $132.95 on Nov 1, 2021.
Is Bio-Techne stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Bio-Techne the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.